Adam Kinnaird, MD, PhD, FRCSC, presented “Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance” during the 8th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8, 2024.
How to cite: Kinnaird, Adam. “Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance.” October 8, 2024. Accessed Jan 2025. https://grandroundsinurology.com/utility-of-micro-ultrasound-in-prostate-cancer-active-surveillance/
Utility of Micro-Ultrasound in Prostate Cancer Active Surveillance – Summary
Adam Kinnaird, MD, PhD, FRCSC, discusses micro-ultrasound’s utility in active prostate cancer surveillance. In this 11-minute presentation, he outlines the evolution of prostate biopsy techniques and highlights micro-ultrasound’s ability to provide high-resolution imaging that detects prostate cancers invisible to conventional ultrasound. The Primus Scoring System, akin to the PI-RADS system for MRI, aids in classifying findings with promising accuracy in detecting clinically significant prostate cancer.
Dr. Kinnaird presents comparative studies showing micro-ultrasound as non-inferior to MRI in biopsy-naive patients. Preliminary data from trials reveal high concordance between micro-ultrasound and MRI. He highlights advancements in artificial intelligence, such as AI-driven heat maps for targeted biopsies, which show potential for improving diagnostic accuracy in both biopsy-naive and active surveillance settings.
The talk emphasizes the promise of micro-ultrasound in reducing overdiagnosis, improving patient outcomes, and potentially complementing or replacing MRI in specific clinical contexts.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Dr. Adam Kinnaird, MD, PhD, FRCSC is a surgeon and scientist, currently appointed as an assistant professor in the Department of Surgery in the Faculty of Medicine & Dentistry at University of Alberta in Edmonton, Alberta, Canada. Dr. Kinnaird also serves as the Chair of The Alberta Prostate Cancer Research Initiative (APCaRI) and the Frank and Carla Sojonky Chair in Prostate Cancer Research in the Division of Urology, Department of Surgery at theUniversity of Alberta.
Dr. Kinnaird completed his MD and urology residency at the University of Alberta, during which he was enrolled in the Clinician Investigator Program. He earned his PhD as a Vanier Scholar and was awarded the Governor General’s Gold Medal in research in 2018. He then completed a fellowship in imaging, targeted biopsy, and focal therapy for prostate cancer at UCLA.
He has published in high-impact journals such asNature Reviews Cancer,Cell, andEuropean Urologyand has been awarded funding from local, regional, and national grant competitions. Dr. Kinnaird is also a member of the Alberta Prostate Cancer Research Initiative (APCaRI) and Cancer Research Institute of Northern Alberta (CRINA). Currently, Dr. Kinnaird’s research interests include translational prostate cancer research with a focus on new drugs, technologies, and devices.
